首页> 美国卫生研究院文献>Open Forum Infectious Diseases >1520. Respiratory Syncytial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among Children Aged ≤ 24 Months at the Start of RSV Season With Bronchopulmonary Dysplasia/Chronic Lung Disease of Prematurity (BPD/CLDP) Before and After the 2014 American Academy of Pediatrics (AAP) Policy
【2h】

1520. Respiratory Syncytial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among Children Aged ≤ 24 Months at the Start of RSV Season With Bronchopulmonary Dysplasia/Chronic Lung Disease of Prematurity (BPD/CLDP) Before and After the 2014 American Academy of Pediatrics (AAP) Policy

机译:1520.在2014年和之后在2014年之前和之后在RSV季节开始时呼吸道同性恋病毒住院(RSVH)和全导致的支气管炎住院(BH)≤24个月的儿童≤24个月。在2014年之前和之后的早产儿(BPD / CLDP)儿科学院(AAP)政策

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The AAP, in 2014, stopped endorsing palivizumab for use in children with BPD/CLDP born at < 32 weeks’ gestational age (wGA) between the ages of 12 to 24 months not requiring medical support during the 6 months before the start of RSV season and all children with BPD/CLDP born at > 32 wGA. We sought to understand the impact of the guidance change on RSVH and BH in children no longer advised for RSV immunoprophylaxis with palivizumab.
机译:2014年,AAP已止于批准帕尔韦姆布,以便在BPD / CLDP中使用BPD / CLDP在<32周内出生的儿童(WGA)在12至24个月之间,在RSV季节开始前6个月内不需要医疗支持所有有BPD / CLDP的孩子出生于> 32 WGA。我们试图了解指导变化对RSVH和BH的影响,儿童不再建议RSV免疫促妇虫与Palivizumab。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号